A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US*

Author： Charles Meaghan St.   Minshall Michael E.   Pandya Bhavik J.   Baran Robert W.   Tunis Sandra L.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.6, 2009-06, pp. : 1343-1353

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparing the Long-term Cost-effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients with Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 Diabetes

By Palmer Andrew J.   Roze Stéphane   Lammert Morten   Valentine William J.   Minshall Michael E.   Nicklasson Lars   Gall Mari-Anne   Spinas Giatgen A.  

Current Medical Research and Opinion, Vol. 20, Iss. 1, 2004-08 ,pp. : 41-51

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US**

By Tunis Sandra L.   Minshall Michael E.   St. Charles Meaghan   Pandya Bhavik J.   Baran Robert W.  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3085-3096

Informa Healthcare

Access to resources Recommend Favorite

Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study

By Lundborg Mikael   Wille Sören   Bjermer Leif   Tilling Björn   Lundgren Michael   Telg Gunilla   Ekström Tommy   Selroos Olof  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 809-821

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis*

By Tunis Sandra L.   Minshall Michael E.   Conner Christopher   McCormick John I.   Kapor Jovana   Yale Jean-François   Groleau Danielle  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1273-1284

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial

By Kaku Kohei  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1111-1119

Informa Healthcare

Access to resources Recommend Favorite